IDSA, CDC, and international ID guidelines.

10 topics · 17 versions · 3 high-yield

← back to all systems

Adult immunization ⭐

adult-immunization · society: CDC/ACIP · high-yield

2025 CDC/ACIP Adult Immunization Schedule (addendum updated July 2, 2025) for adults aged ≥19 years. Organized by age group (19–26, 27–49, 50–64, ≥65) and by medical condition, covering routine, risk-based, and shared clinical decision-making vaccines including COVID-19, influenza, RSV, Tdap, MMR, varicella, zoster, HPV, pneumococcal, hepatitis A/B, meningococcal, Hib, mpox, and IPV.

Antimicrobial stewardship

antimicrobial-stewardship · society: IDSA/SHEA

IDSA/SHEA 2016 guideline on implementing antibiotic stewardship programs (ASPs) in acute inpatient, long-term care, and ED settings. Provides 28 GRADE-rated recommendations across interventions, optimization, microbiology/diagnostics, measurement, and special populations. Emphasizes preauthorization and/or prospective audit and feedback as core ASP activities led by ID physicians with pharmacist partners.

Candidiasis

candidiasis · society: IDSA

2016 IDSA update on management of candidiasis covering candidemia, invasive candidiasis, and mucosal disease across neutropenic, nonneutropenic, ICU, neonatal, and special-site populations. Major change from 2009 is the elevation of echinocandins to first-line therapy for most candidemia and invasive candidiasis, with fluconazole reserved for selected stable, azole-naive patients. Adds guidance on β-D-glucan and PCR diagnostics, and updates recommendations for endocarditis, endophthalmitis, CNS, intra-abdominal, and urinary tract candidiasis.

COVID-19

covid-19

IDSA living guideline on pharmacologic treatment and prevention of COVID-19, updated through October 2025. Covers antiviral selection for mild-to-moderate disease (nirmatrelvir/ritonavir preferred, then remdesivir, then molnupiravir), immunomodulator selection for severe/critical hospitalized disease (corticosteroids plus baricitinib or tocilizumab; abatacept or infliximab as alternatives), and pre-exposure prophylaxis with pemivibart in immunocompromised hosts. Recommendations against hydroxychloroquine, lopinavir/ritonavir, ivermectin, colchicine, famotidine, and routine convalescent plasma in immunocompetent hospitalized patients.

HIV (antiretroviral therapy) ⭐

hiv · high-yield

The IAS-USA 2024 panel updates recommendations for antiretroviral therapy and HIV prevention in adults. ART is recommended for all individuals with HIV, with bictegravir- or dolutegravir-based InSTI regimens plus 2 NRTIs (TXF/XTC) as preferred initial therapy; DTG/3TC is the only recommended 2-drug initial option. New elements include broader statin use for ASCVD primary prevention (per REPRIEVE), doxycycline PEP for bacterial STI prevention, long-acting cabotegravir for PrEP, and integrated management of substance use disorders, weight gain, and cardiometabolic comorbidities.

Infective endocarditis

infective-endocarditis

AHA 2023 Science Advisory revisiting the link between nondental invasive procedures (NDIPs) and infective endocarditis (IE) risk, prompted by large nationwide case-crossover studies from Sweden (Janszky 2018) and England (Thornhill 2022) showing temporal association between several NDIPs and subsequent IE in high-risk patients. The advisory does not change current AHA guidance (which since 2007 restricts antibiotic prophylaxis [AP] to invasive dental procedures in high-risk patients) but calls for future guideline committees to reconsider AP, infection-prevention measures, and clinician awareness for NDIPs in high-risk individuals. No new prophylaxis regimens are mandated.

  • 2023 · AHA — AHA 2023 IE Update
  • 2023 · ESC — ESC 2023 IE Guideline
    • Read the guideline: html
  • 2023 · Duke-ISCVID — Duke-ISCVID 2023 Diagnostic Criteria
    • Read the guideline: html
  • 2015 · AHA — AHA 2015 IE Guideline
    • Read the guideline: html

Skin & soft tissue infections

ssti · society: IDSA

2014 IDSA update on diagnosis and management of skin and soft tissue infections (SSTIs), updating the 2005 guideline and aligned with IDSA’s MRSA guideline. Stratifies purulent vs nonpurulent SSTIs into mild/moderate/severe categories driving incision-and-drainage and antibiotic selection. Covers impetigo, abscesses, cellulitis/erysipelas, necrotizing fasciitis, pyomyositis, gas gangrene, surgical site infections, animal/human bites, zoonotic SSTIs, and SSTIs in immunocompromised and neutropenic hosts.

Sexually transmitted infections

sti · society: CDC

Comprehensive CDC update of the 2015 STD treatment guidelines covering screening, diagnosis, and treatment of STIs across populations. Key updates include single-dose ceftriaxone 500 mg for gonorrhea, doxycycline preferred over azithromycin for chlamydia, addition of metronidazole to PID regimens, multidose metronidazole for trichomoniasis in women, resistance-guided two-stage therapy for M. genitalium, expanded syphilis screening in pregnancy, universal one-time HCV screening, and two-step HSV serologic testing.

Tuberculosis (active / latent)

tuberculosis

2020 NTCA/CDC update to the 2000 ATS/CDC latent TB infection (LTBI) treatment guidelines, based on GRADE systematic review and network meta-analysis. Short-course (3–4 month) rifamycin-based regimens are now preferred over 6–9 months of isoniazid monotherapy because of equivalent efficacy, lower hepatotoxicity, and higher completion rates. Applies only to LTBI presumed susceptible to isoniazid or rifampin (not MDR-TB contacts).

Urinary tract infection ⭐

uti · society: IDSA · high-yield

2019 IDSA update on management of asymptomatic bacteriuria (ASB), defined as ≥10⁵ CFU/mL in urine without UTI symptoms. Updates the 2005 guideline and adds new populations (children, solid organ transplant, neutropenia, nonurologic surgery) plus guidance on interpreting nonlocalizing symptoms (delirium, falls) in older adults. Core message: do NOT screen or treat ASB except in pregnancy and before endoscopic urologic procedures involving mucosal trauma; emphasis on antimicrobial stewardship.

Table of contents